TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12933408
Drug: Droperidol 15
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droperidol 15 micro g
Study: 12933408
Drug: Droperidol 50
Normalized name: fentanyl citrate/droperidol 50 mcg-2.5 mg/mL INJECTION AMPUL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 50 micro g
Study: 30091814
Drug: Therapeutic Education
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Education System (TES) and treatment-as-usual (control).
Study: 30091814
Drug: Treatment-as-usual (control).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (control).
Study: 18498916
Drug: MPA AUC(0‐12h)
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA AUC(0‐12h) ranges >60 mg/L x h(‐1)
Study: 18498916
Drug: MPA AUC(0‐12h)
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA AUC(0‐12h) ranges <30 mg/L x h(‐1), 30‐60 mg/L x h(‐1), >60 mg/L x h(‐1)
Study: 18498916
Drug: MPA AUC(0‐12
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA AUC(0‐12 h) ranges <30, 30‐60, >60 mg/L x h(‐1)
Study: 10561191
Drug: G-CSF and
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF and G-CSF + EPO
Study: 8777066
Drug: Maintenance group
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance group received calls twice a month for six months
Study: 1890155
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg DHSP
Study: 9272426
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg cyproterone acetate
Study: 3882480
Drug: Squaric acid
Normalized name: Squaric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Squaric acid dibutyl ester (SADBE) treatment on the right side of the scalp
Study: 31718637
Drug: Antifibrotic drugs
Normalized name: Antihidrotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrotic drugs (10 patients treated with pirfenidone at 2403 mg/day, 1 patient with nintedanib at 300 mg/day)
Study: 30630794
Drug: Combined medication
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medication of abraxane and trastuzumab
Study: 30630794
Drug: Single medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single medication of trastuzumab
Study: 26975590
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (initiated within 24 hours after ICU admission)
Study: 26975590
Drug: Late parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late parenteral nutrition (initiated on the morning of the 8th day in the ICU)
Study: 23619160
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D₃ supplementation (2000 IU per day)
Study: 16260696
Drug: High-dose tumor
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tumor cell vaccine
Study: 16260696
Drug: Low-dose tumor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tumor cell vaccine
Study: 9844331
Drug: Occlusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusion therapy
Study: 29502374
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg per day for 9 weeks
Study: 29502374
Drug: Pemetrexed combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed combined with cisplatin chemotherapy (2 cycles followed by 3-week discontinuation)
Study: 29502374
Drug: Neoadjuvant targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant targeted therapy group
Study: 29502374
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy group
Study: 22490487
Drug: Resistance plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance plus loading dose group (R + L): 200 mg aspirin and 150 mg clopidogrel per day
Study: 22490487
Drug: Resistance plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance plus routine dose group (R + R): 100 mg aspirin plus 75 mg clopidogrel per day
Study: 20018367
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL of the pandemic vaccine (Fluval P, a monovalent vaccine with 6 microg haemagglutinin per 0.5 mL content and aluminium phosphate gel adjuvant; n=178)
Study: 20018367
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL of the pandemic vaccine and 0.5 mL of the seasonal trivalent vaccine (Fluval AB, a trivalent inactivated whole-virion influenza vaccine; n=177)
Study: 17373172
Drug: 5% 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-fluorouracil cream
Study: 9533423
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (captopril up to 100 mg/day + 5 mg bendrofluazide)
Study: 2655909
Drug: Dyazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyazide (25 mg hydrochlorothiazide and 50 mg triamterene), one capsule daily for eight weeks
Study: 2655909
Drug: Placebo, one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one capsule daily for eight weeks
Study: 18081732
Drug: DDP733 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP733 0.5 mg
Study: 18081732
Drug: DDP733 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP733 0.8 mg
Study: 18081732
Drug: DDP733 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDP733 1.4 mg
Study: 15080819
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment (0.1%) given twice a day
Study: 15080819
Drug: Oral cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporine (3 mg/kg) given once daily
Study: 24885317
Drug: Telephone counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone counselling intervention by pharmacist 2 or 3 weeks after a new prescription.
Study: 17952423
Drug: Halofantrine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (500 mg) with kolanut (12.5 g)
Study: 17952423
Drug: Halofantrine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (500 mg) alone
Study: 12439119
Drug: Omeprazole triple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole triple therapy (OAC: omeprazole 20 mg b.d., amoxicillin 1 g b.d., clarithromycin 0.5 g b.d.)
Study: 12439119
Drug: Omeprazole quadruple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole quadruple therapy (OBMT: omeprazole 20 mg b.d., colloidal bismuth subcitrate 120 mg q.i.d., metronidazole 0.5 g t.i.d., tetracycline hydrochloride 0.5 g q.i.d.)
Study: 2266673
Drug: L-lactate (46
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lactate (46 mM)
Study: 7420419
Drug: Restricted environmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted environmental stimulation therapy (lying on a bed in a dark, silent room) combined with self-management messages
Study: 26393386
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day istradefylline plus sham‐rTMS
Study: 26393386
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day istradefylline plus sham‐rTMS
Study: 24193859
Drug: Home-based infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based infusion therapy (ERT with agalsidase alfa every two weeks)
Study: 3301457
Drug: twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily sustained release theophylline suspension
Study: 3301457
Drug: standard twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard twice daily slow release tablets
Study: 29783914
Drug: Fist Assist®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fist Assist® device applied 15 cm proximal to arteriovenous fistula, enabling 60 mmHg of cyclic compression for 6 hours daily for 30 days
Study: 27464712
Drug: Liquid emulsion
Normalized name: propofol lipid emulsion Injection [Propoven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid emulsion of coenzyme Q10 (250 mg daily for 1 week)
Study: 27464712
Drug: Solid formulation
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid formulation of coenzyme Q10 (250 mg daily for 1 week)
Study: 27464712
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (liquid emulsion and solid)
Study: 25406242
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in carbohydrate intake (≤9.5 g/d)
Study: 15562791
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) for more than 1 year
Study: 8301062
Drug: Imidazole-salicylate (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidazole-salicylate (750 mg)
Study: 3329078
Drug: Neo Sampoon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo Sampoon foaming vaginal contraceptive tablets
Study: 28440105
Drug: Doxazosin 8
Normalized name: doxazosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 8 mg/day
Study: 12664317
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg, 2 times daily for 12 days
Study: 12664317
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg for 12 days
Study: 1718699
Drug: Diltiazem and
Normalized name: Diltiazem and enalapril only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem and aspirin administration
Study: 7103635
Drug: Fluoxymesterone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxymesterone (30 mg/day) plus necessary transfusions
Study: 18534135
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg once a day for up to 28 days
Study: 18534135
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg once a day for up to 28 days
Study: 18534135
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diclofenac 50 mg twice a day for 10 days (Control)
Study: 12450889
Drug: Caffeine treatment
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine treatment (870 mg caffeine/d)
Study: 12450889
Drug: Coffee treatment
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee treatment (0.9 L paper-filtered coffee providing approximately 870 mg caffeine/d)
Study: 12450889
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (3 placebo capsules)
Study: 12450889
Drug: Coffee treatment
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee treatment (0.45 L coffee)
Study: 9807846
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration of tenoxicam (10 mg in 10 ml normal saline)
Study: 9807846
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam (20 mg)
Study: 9807846
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam (10 mg)
Study: 9807846
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no preoperative local infiltration or intravenous tenoxicam)
Study: 2611126
Drug: Clinitar (purified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinitar (purified coal tar cream)
Study: 415880
Drug: NH4Cl administration
Normalized name: Ammonium Chloride
DrugBank: Ammonium chloride (DB06767)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NH4Cl administration
Study: 31931160
Drug: Inhaled Lavandula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Lavandula angustifolia Mill. Essential oil
Study: 30156312
Drug: Firocoxib (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firocoxib (0.3 mg/kg, i.v. loading dose; 0.1 mg/kg, i.v., q24h)
Study: 30156312
Drug: Flunixin meglumine
Normalized name: Flunixin Meglumine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunixin meglumine (1.1 mg/kg, i.v., q12h)
Study: 28479288
Drug: Concurrent Foley
Normalized name: CATHETER,FOLEY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Foley bulb and oxytocin
Study: 26542513
Drug: Prasugrel pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel pretreatment (30 mg loading dose)
Study: 22710541
Drug: 5% KOH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% KOH solution
Study: 17264849
Drug: Topiramate 96
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 96 mg b.i.d.
Study: 15230906
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ibuprofen and 1000 mg acetaminophen
Study: 9164365
Drug: Placebo acaricide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo acaricide treatment combined with avoidance measures
Study: 1975487
Drug: Zidovudine, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, 500 mg orally every 4 hours for 12 weeks, combined with six peripheral blood lymphocyte infusions and bone marrow transplantation
Study: 1975487
Drug: Zidovudine, 100
Normalized name: Zidovudine, 100 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine, 100 mg every 4 hours for 12 months
Study: 22268972
Drug: 5-weekly group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-weekly group mantram intervention
Study: 15854171
Drug: Ipocol (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipocol (2.4 g daily for 8 weeks)
Study: 15854171
Drug: Asacol (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol (2.4 g daily for 8 weeks)
Study: 14521276
Drug: Neurofeedback (NFB)
Normalized name: NFBA
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neurofeedback (NFB) treatment applied in the region with the highest theta/alpha ratio, triggering a sound when the ratio fell below a threshold value, 20 half-hour sessions at a rate of 2 per week.
Study: 7593419
Drug: Carbenoxolone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (100 mg every 8 h for 7 days)
Study: 2182032
Drug: 2-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose insulin regimen (mainly intermediate acting insulin before breakfast and dinner)
Study: 2182032
Drug: 4-dose insulin
Normalized name: insulin, regular, human 4 UNT [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-dose insulin regimen (regular insulin preprandially with intermediate acting insulin at bedtime)
Study: 2182032
Drug: 2-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose insulin regimen
Study: 2182032
Drug: 4-dose insulin
Normalized name: insulin, regular, human 4 UNT [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-dose insulin regimen
Study: 2182032
Drug: 2-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose insulin regimen and 4-dose insulin regimen
Study: 396655
Drug: LS 519
Normalized name: Emcor LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: LS 519 (75 mg/day)
Study: 396655
Drug: LS 519
Normalized name: Emcor LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: LS 519 (150 mg/day)
Study: 396655
Drug: Carbenoxolone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (300 mg/day)
Study: 24226711
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg/d for 3 days)
Study: 17556414
Drug: Lead-chelation therapy
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead-chelation therapy with calcium disodium EDTA
Study: 17556414
Drug: Lead-chelation therapy
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead-chelation therapy
Study: 17556414
Drug: Repeated chelation
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated chelation therapy
Study: 14764176
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (mainly amiodarone)
Study: 9337166
Drug: Subcutaneous port
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous port insertion
Study: 8202898
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg with flurbiprofen 200 mg
Study: 2438319
Drug: Inosiplex (isoprinosine)
Normalized name: Inosiplex
DrugBank: Inosine pranobex (DB13156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosiplex (isoprinosine) therapy for 20 weeks
Study: 24237190
Drug: Chromium plus
DrugBank: Vanadium (DB13971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium plus sertraline
Study: 21168715
Drug: CNI discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNI discontinuation
Study: 11049917
Drug: Cisatracurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium 0.2 mg/kg IV bolus, followed by infusion
Study: 11049917
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg IV, followed by infusion
Study: 8831436
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interpersonal psychotherapy and tricyclic antidepressant (nortriptyline for elderly, imipramine for midlife) during acute-phase therapy
Study: 8831436
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment with the same therapy
Study: 22651541
Drug: Fluticasone propionate-salmeterol
Normalized name: Fluticasone Propionate/Salmeterol Xinafoate 55 MCG/1 ACTUATION-14 MCG/1 ACTUATION Inhalation Powder [FLUTICASONE PROPIONATE-SALMETEROL XINAFOATE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate-salmeterol 250/50 mcg (FSC)
Study: 14693626
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 2.5 mg (group B)
Study: 14693626
Drug: Intrathecal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal ropivacaine 2.5 mg (group R)
Study: 14693626
Drug: Intrathecal levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal levobupivacaine 2.5 mg (group L)
Study: 9520073
Drug: New levodopa/benserazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: New levodopa/benserazide formulation (Madopar DR)
Study: 9520073
Drug: New levodopa/benserazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: New levodopa/benserazide formulation (Madopar DR) after standard breakfast
Study: 9520073
Drug: New levodopa/benserazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: New levodopa/benserazide formulation (Madopar DR) in fasted condition
Study: 9520073
Drug: New levodopa/benserazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: New levodopa/benserazide formulation (Madopar DR) with food
Study: 7737238
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tiracizine hydrochloride
Study: 7737238
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tiracizine hydrochloride
Study: 7737238
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tiracizine hydrochloride
Study: 7737238
Drug: Tiracizine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiracizine (all doses)
Study: 7737238
Drug: Tiracizine (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiracizine (serum concentrations about 80 ng/ml)
Study: 2537562
Drug: Enalapril plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril plus diuretics (n = 72)
Study: 2537562
Drug: Digoxin plus
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin plus diuretics (n = 70)
Study: 31748939
Drug: Pre-release methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-release methadone treatment
Study: 26179184
Drug: Inotropic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotropic therapy (Milrinone in 84.8% and Dobutamine in 15.2%)
Study: 26179184
Drug: Inotropic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inotropic therapy as a bridge to transplant/LVAD
Study: 20833488
Drug: Dietary soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary soy supplementation (90 mg of isoflavone)
Study: 20833488
Drug: Low-dose hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose hormone therapy (1mg estradiol and 0.5mg norethisterone acetate)
Study: 18408610
Drug: Methylphenidate (MPH;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (MPH; Ritalin; 20 mg)
Study: 18408610
Drug: Placebo (PLA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA; 20 mg)
Study: 15651723
Drug: Once-daily regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily regimen of 2 mg trichlormethiazide
Study: 15651723
Drug: Twice-daily regimen
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily regimen of 2 mg trichlormethiazide
Study: 10891662
Drug: Suppressive doses
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive doses of levothyroxine for 18 months
Study: 7503088
Drug: Suppressive doses
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive doses of levothyroxine
Study: 1846783
Drug: Endothelin-1 (ET)
Normalized name: nitric oxide synthase endothelial
DrugBank: Endothelin-1 (DB12652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin-1 (ET) infusion at low dose (0.5 ng/min/100 ml forearm tissue)
Study: 1846783
Drug: Endothelin-1 (ET)
Normalized name: nitric oxide synthase endothelial
DrugBank: Endothelin-1 (DB12652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin-1 (ET) infusion at high doses (25 and 50 ng/min/100 ml forearm tissue)
Study: 1846783
Drug: Nifedipine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (6 micrograms/min/100 ml forearm tissue)